Gharib E, Rejali L, Piroozkhah M, Zonoobi E, Nasrabadi P, Arabsorkhi Z
J Transl Med. 2024; 22(1):439.
PMID: 38720389
PMC: 11080123.
DOI: 10.1186/s12967-024-05251-2.
Ott de Bruin L, Lankester A, Staal F
Curr Opin Allergy Clin Immunol. 2023; 23(6):467-477.
PMID: 37846903
PMC: 10621649.
DOI: 10.1097/ACI.0000000000000952.
Bastani S, Staal F, Cante-Barrett K
Stem Cell Investig. 2023; 10:15.
PMID: 37457748
PMC: 10345135.
DOI: 10.21037/sci-2023-016.
Blanco E, Izotova N, Booth C, Thrasher A
Front Immunol. 2020; 11:608653.
PMID: 33329605
PMC: 7729079.
DOI: 10.3389/fimmu.2020.608653.
Villa A, Capo V, Castiello M
Front Immunol. 2020; 11:607926.
PMID: 33329604
PMC: 7711106.
DOI: 10.3389/fimmu.2020.607926.
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.
Garcia-Perez L, van Eggermond M, van Roon L, Vloemans S, Cordes M, Schambach A
Mol Ther Methods Clin Dev. 2020; 17:666-682.
PMID: 32322605
PMC: 7163047.
DOI: 10.1016/j.omtm.2020.03.016.
Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives.
Staal F, Aiuti A, Cavazzana M
Front Pediatr. 2019; 7:443.
PMID: 31737588
PMC: 6834641.
DOI: 10.3389/fped.2019.00443.
Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?.
Ginn S, McCormack M, Alexander I
Mamm Genome. 2018; 29(11-12):771-776.
PMID: 30182300
DOI: 10.1007/s00335-018-9780-5.
Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
Hiramoto T, Li L, Funk S, Hirata R, Russell D
Mol Ther. 2018; 26(5):1255-1265.
PMID: 29606506
PMC: 5993949.
DOI: 10.1016/j.ymthe.2018.02.028.
Gene Therapy for the Treatment of Primary Immune Deficiencies.
Kuo C, Kohn D
Curr Allergy Asthma Rep. 2016; 16(5):39.
PMID: 27056559
PMC: 5909980.
DOI: 10.1007/s11882-016-0615-8.
Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders.
Wagemaker G
Hum Gene Ther. 2014; 25(10):862-5.
PMID: 25184354
PMC: 4179920.
DOI: 10.1089/hum.2014.102.
Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.
Romano G
ISRN Oncol. 2012; 2012:616310.
PMID: 23209944
PMC: 3512301.
DOI: 10.5402/2012/616310.
Engineering humanized mice for improved hematopoietic reconstitution.
Drake A, Chen Q, Chen J
Cell Mol Immunol. 2012; 9(3):215-24.
PMID: 22425741
PMC: 4081442.
DOI: 10.1038/cmi.2012.6.
Retroviral integrations in gene therapy trials.
Biasco L, Baricordi C, Aiuti A
Mol Ther. 2012; 20(4):709-16.
PMID: 22252453
PMC: 3321603.
DOI: 10.1038/mt.2011.289.
Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
Huston M, van Til N, Visser T, Arshad S, Brugman M, Cattoglio C
Mol Ther. 2011; 19(10):1867-77.
PMID: 21750532
PMC: 3188737.
DOI: 10.1038/mt.2011.127.
Novel insights into the development of T-cell acute lymphoblastic leukemia.
Staal F, van Dongen J, Langerak A
Curr Hematol Malig Rep. 2010; 2(3):176-82.
PMID: 20425367
DOI: 10.1007/s11899-007-0024-0.
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.
Arumugam P, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P
Mol Ther. 2009; 17(11):1929-37.
PMID: 19707188
PMC: 2835044.
DOI: 10.1038/mt.2009.183.
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Dave U, Akagi K, Tripathi R, Cleveland S, Thompson M, Yi M
PLoS Genet. 2009; 5(5):e1000491.
PMID: 19461887
PMC: 2679194.
DOI: 10.1371/journal.pgen.1000491.
Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M, Stephen S, Knight S, Gevers E, Robinson I, Takeuchi Y
J Virol. 2008; 83(1):283-94.
PMID: 18945765
PMC: 2612344.
DOI: 10.1128/JVI.01865-08.
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E
J Clin Invest. 2008; 118(9):3132-42.
PMID: 18688285
PMC: 2496963.
DOI: 10.1172/JCI35700.